Logo image of ZYME

ZYMEWORKS INC (ZYME) Stock Fundamental Analysis

NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD

12  -0.13 (-1.07%)

After market: 12 0 (0%)

Fundamental Rating

2

ZYME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While ZYME seems to be doing ok healthwise, there are quite some concerns on its profitability. ZYME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZYME had negative earnings in the past year.
In the past year ZYME has reported a negative cash flow from operations.
ZYME had negative earnings in 4 of the past 5 years.
In the past 5 years ZYME reported 4 times negative operating cash flow.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

With a decent Return On Assets value of -23.33%, ZYME is doing good in the industry, outperforming 74.17% of the companies in the same industry.
ZYME has a better Return On Equity (-30.97%) than 77.31% of its industry peers.
Industry RankSector Rank
ROA -23.33%
ROE -30.97%
ROIC N/A
ROA(3y)-18.57%
ROA(5y)-25.75%
ROE(3y)-28.45%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZYME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ZYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 1.82 indicates that ZYME is not a great score, but indicates only limited risk for bankruptcy at the moment.
ZYME has a Altman-Z score of 1.82. This is in the better half of the industry: ZYME outperforms 72.25% of its industry peers.
ZYME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ZYME has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.82
ROIC/WACCN/A
WACC10.57%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.10 indicates that ZYME has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.10, ZYME is in line with its industry, outperforming 47.64% of the companies in the same industry.
A Quick Ratio of 4.10 indicates that ZYME has no problem at all paying its short term obligations.
The Quick ratio of ZYME (4.10) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 4.1
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.65% over the past year.
EPS 1Y (TTM)19.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.33%

3.2 Future

Based on estimates for the next years, ZYME will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.67% on average per year.
The Revenue is expected to grow by 21.71% on average over the next years. This is a very strong growth
EPS Next Y-25.65%
EPS Next 2Y12.63%
EPS Next 3Y-7.01%
EPS Next 5Y8.67%
Revenue Next Year-1%
Revenue Next 2Y40.73%
Revenue Next 3Y17.73%
Revenue Next 5Y21.71%

3.3 Evolution

ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZYME. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

ZYME's earnings are expected to decrease with -7.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.63%
EPS Next 3Y-7.01%

More info and screens

0

5. Dividend

5.1 Amount

ZYME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYMEWORKS INC

NASDAQ:ZYME (3/7/2025, 8:00:02 PM)

After market: 12 0 (0%)

12

-0.13 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2025-03-05/amc
Earnings (Next)04-30 2025-04-30
Inst Owners96.56%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change2.34%
Market Cap834.96M
Analysts84.29
Price Target20.85 (73.75%)
Short Float %5.76%
Short Ratio8.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.88%
Min EPS beat(2)3.34%
Max EPS beat(2)16.42%
EPS beat(4)3
Avg EPS beat(4)8.14%
Min EPS beat(4)-41.99%
Max EPS beat(4)54.79%
EPS beat(8)5
Avg EPS beat(8)2.12%
EPS beat(12)9
Avg EPS beat(12)9.64%
EPS beat(16)12
Avg EPS beat(16)9.58%
Revenue beat(2)1
Avg Revenue beat(2)-1.8%
Min Revenue beat(2)-6.1%
Max Revenue beat(2)2.5%
Revenue beat(4)2
Avg Revenue beat(4)-9.94%
Min Revenue beat(4)-43.59%
Max Revenue beat(4)7.41%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)6
Avg Revenue beat(12)6.55%
Revenue beat(16)7
Avg Revenue beat(16)-5.01%
PT rev (1m)0%
PT rev (3m)12.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.79%
EPS NY rev (1m)0%
EPS NY rev (3m)1.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.42
P/FCF N/A
P/OCF N/A
P/B 2.28
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.89
BVpS5.27
TBVpS5.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.33%
ROE -30.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.57%
ROA(5y)-25.75%
ROE(3y)-28.45%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.98%
Cap/Sales 7.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 4.1
Altman-Z 1.82
F-Score3
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)142.22%
Cap/Depr(5y)153.4%
Cap/Sales(3y)19.45%
Cap/Sales(5y)24.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
EPS Next Y-25.65%
EPS Next 2Y12.63%
EPS Next 3Y-7.01%
EPS Next 5Y8.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.33%
Revenue Next Year-1%
Revenue Next 2Y40.73%
Revenue Next 3Y17.73%
Revenue Next 5Y21.71%
EBIT growth 1Y-159.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.19%
EBIT Next 3Y9.82%
EBIT Next 5YN/A
FCF growth 1Y76.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.68%
OCF growth 3YN/A
OCF growth 5YN/A